Where should we focus?
Competitive landscapes
Compare assets, indications, and competitors. Understand the evidence behind the opportunity.
Strategic intelligence for biopharma
Epistemic AI produces source-linked competitive landscapes, target product profiles, and conference intelligence for biopharma teams.
Our AI agents and scientists analyze connected evidence together. Choose it for strategic decisions; a general-purpose tool may suit a quick document summary.
Updated
4
of the largest pharmaceutical companies are Epistemic clients. As of September 2026.
10B+ nodes 25B+ edges
in the Epistemic Knowledge Graph, as of September 2026. See the platform
Nature Reviews Drug Discovery
published our analysis of a decade of clinical trial terminations in its 2026 volume. Read the paper
Solutions
More evidence, sooner. More options before you commit. Start with the question your team needs to answer.
Where should we focus?
Compare assets, indications, and competitors. Understand the evidence behind the opportunity.
How will we differentiate?
Define your product against clinical and commercial benchmarks, with the reasoning made clear.
What changes our strategy?
Know what changed and what it means. Put new evidence in the context of your competitive landscape.
We can walk your team through a redacted competitive landscape, target product profile, conference intelligence, and real-world evidence analysis.
Delivered as dashboards, reports, executive decks, or structured data.
Request a walkthroughIn practice
Work starts with one question and expands as the connected evidence builds up.
Competitive intelligence
An oncology landscape grew into TPPs, conference intelligence, target identification, and portfolio trend analysis.
Target product profiles
Our target product profile won a head-to-head evaluation at a top-20 pharma company.
Conference intelligence
Readiness and evidence updates for a top-20 pharma company.
Results from individual programs, described without client names. These examples were confirmed for publication as of September 2026. Timing depends on scope, evidence availability, and scientific review.
Your next decision starts here
Bring us your question. We reply within one business day and help define the analysis that moves you forward.